Loading…
Loading…
TTOO does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for TTOO and 80,000+ other tickers.
See exactly how TTOO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for TTOO and 80,000+ other tickers.
T2 Biosystems, Inc. is an in vitro diagnostics company that develops and commercializes innovative diagnostic solutions for global markets. Its proprietary technology platform enables the rapid detection of pathogens, biomarkers, and other critical abnormalities directly from a wide array of unpurified patient specimens, including whole blood, plasma, serum, saliva, sputum, cerebrospinal fluid, and urine. The company's commercial offerings include the T2Dx Instrument, a compact bench-top system designed to run various diagnostic assays. Its current suite of diagnostic tests features…
T2 Biosystems (NASDAQ: TTOO - Get Free Report) and Biostage (OTCMKTS:BSTG - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings. Earnings and Valuation This table compares T2 Biosystems
Risk and Volatility Acutus Medical has a beta of -1.28, meaning that its stock price is 228% less volatile than the S&P 500. Comparatively, T2 Biosystems has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Profitability This table compares Acutus Medical and T2 Biosystems' net margins,
T2 Biosystems, Inc. (NASDAQ: TTOO - Get Free Report) passed below its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $0.02 and traded as low as $0.0020. T2 Biosystems shares last traded at $0.0020, with a volume of 9,130 shares changing hands. T2 Biosystems
Valuation and Earnings This table compares Minerva Surgical and T2 Biosystems"s revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Minerva Surgical $51.69 million 0.00 -$34.11 million ($8.21) 0.00 T2 Biosystems $7.68 million 0.01 -$50.08 million ($3.89) 0.00 Minerva Surgical has higher revenue and earnings than
Shares of T2 Biosystems, Inc. (NASDAQ: TTOO - Get Free Report) passed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $0.01 and traded as high as $0.0115. T2 Biosystems shares last traded at $0.0110, with a volume of 34,136 shares trading hands. T2 Biosystems